Parabilis Medicines, Inc. PBLS
Parabilis Medicines, Inc. (Nasdaq: PBLS) is an oncology drug developer. Its lead program, Zolucatetide, is in Phase 1 for Desmoid tumors (also FAP, HCC, other Wnt/b-catenin-driven tumors, CRC). Its next catalyst on record is Zolucatetide: Initiation of global registrational Phase 3 trial in desmoid tumors (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Zolucatetide — Initiation of global registrational Phase 3 trial in desmoid tumors (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zolucatetide (b-catenin:TCF inhibitor Helicon) | Desmoid tumors | protein/peptide | Phase 1 |
| Zolucatetide | Familial adenomatous polyposis | protein/peptide | Phase 1 |
| Zolucatetide | Hepatocellular carcinoma | protein/peptide | Phase 1 |
| ERG degrader Helicon | ERG fusion-positive prostate cancer | protein/peptide | Pre-clinical |
| ARON (allosteric AR) degrader Helicon | Metastatic castration-resistant prostate cancer | protein/peptide | Pre-clinical |
Recent results and decisions
- Aug 13, 2026positive Phase 1/2 desmoid data (cut Feb 16, 2026): 74% ORR (14/19 evaluable, incl. one CR), 100% DCR, no SAEs at relevant doses.
74% ORR including one CR: 14 out of 19 patients with ≥2 post-baseline scans responded per RECIST 1.1
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.